Health Care & Life Sciences » Pharmaceuticals | CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc. | Key People and Executives

Sujal Shah
President, Chief Executive Officer & Director
Robert James Wills
Chairman
Caroline M. Loewy
Independent Director
Robert F. G. Booth
Independent Director
Konrad Hans von Emster
Independent Director
Robert J. Weiland
Independent Director
Evan A. Stein
Independent Director
Paul F. Truex
Independent Director
Carl Samuel Goldfischer
Independent Director
Sujal Shah
President, Chief Executive Officer & Director
Pol F. Boudes
Chief Medical Officer
Charles A. McWherter
Chief Scientific Officer & Senior Vice President
Daniel Menold
Vice President-Finance
Patrick J. O'Mara
Senior Vice President-Business Development
Paul T. Quinlan
Secretary, Chief Legal Officer & General Counsel
Klara A. Dickinson-Eason
Senior VP-Regulatory Affairs & Quality Assurance
Robert James Wills
Chairman
Caroline M. Loewy
Independent Director
Robert F. G. Booth
Independent Director
Konrad Hans von Emster
Independent Director
Robert J. Weiland
Independent Director
Evan A. Stein
Independent Director
Paul F. Truex
Independent Director
Carl Samuel Goldfischer
Independent Director

About CymaBay Therapeutics

View Profile
Address
7575 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.cymabay.com
Updated 07/08/2019
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.